



[www.pdr.net](http://www.pdr.net)

---

PHYSICIANS'

---

DESK

---

REFERENCE®

---

Dr. Reddy's Laboratories, Ltd., et al.  
v.  
Galderma Laboratories, Inc.  
IPR2015-  
**Exhibit 1042**

RECEIVED  
FEB 15 2000



## PDR.net Content and Features:

### Physicians' Desk Reference®\*

More than 10,000 full text  
articles from Medical Economics  
Company publications including:  
*Medical Economics*®, *Patient Care*®  
and much more...

### Free MEDLINE/AIDSLINE/ CANCERLIT

### PDR.net for Consumers

### PDR's Getting Well Network<sup>SM</sup>


### Online CME/CE

 Medical Economics Company

\*Access to the full, professional version of the PDR® on PDR.net is free for practicing U.S.-based physicians and physician assistants. Consumers can access drug information from the PDR Family Guide to Prescription Drugs®, which is available for free through the PDR.net Supersite consumers' area.

LDLK&M  
LIBRARY  
600 SOUTH AVE. WEST  
WESTFIELD, NJ 07090

The Official  
Home of  
the Physicians'  
Desk Reference  
on the Web





## healthcare information you can trust

When you need healthcare information visit the one site that offers the most – the PDR.net Supersite. Sponsored and maintained by one of the most respected names in health care, you can access the *Physicians' Desk Reference*® as well as thousands of professional healthcare articles from the pages of Medical Economics Company publications. Physicians also benefit from online CME, daily medical news from Reuters, and Stedman's Medical Dictionary. Consumers can take advantage of the *PDR Family Guide to Prescription Drugs*®, daily healthcare news from Reuters, as well as PDR's Getting Well Network – individual, disease-specific sites covering allergy, arthritis, breast cancer, depression, hypertension, osteoporosis, and ear infection/otitis media.

**From the office, your home, or the road, the healthcare information you can trust is always within your reach.**

**[www.pdr.net](http://www.pdr.net)**





# PHYSICIANS' DESK REFERENCE®

**Senior Vice President, Directory Services:** Paul Walsh

**Director of Product Management:** Mark A. Friedman

**Associate Product Manager:** Bill Shaughnessy

**Senior Business Manager:** Mark S. Ritchin

**Financial Analyst:** Wayne M. Soltis

**Director of Sales:** Dikran N. Barsamian

**National Sales Manager, Pharmaceutical Sales:** Anthony Sorce

**National Account Manager:** Don Bruccoleri

**Senior Account Manager:** Frank Karkowsky

**Account Managers:**

Marion Gray, RPh

Lawrence C. Keary

Jeffrey F. Pfohl

Suzanne E. Yarrow, RN

**Electronic Sales Account Manager:** Stephen M. Silverberg

**National Sales Manager, Medical Economics Trade Sales:** Bill Gaffney

**Director of Direct Marketing:** Michael Bennett

**List and Production Manager:** Lorraine M. Loening

**Senior Marketing Analyst:** Dina A. Maeder

**Director, New Business Development and**

**Professional Support Services:** Mukesh Mehta, RPh

**Manager, Drug Information Services:** Thomas Fleming, RPh

**Drug Information Specialist:** Maria Deutsch, MS, RPh, CDE

**Editor, Directory Services:** David W. Sifton

**Senior Associate Editor:** Lori Murray

**Director of Production:** Carrie Williams

**Manager of Production:** Kimberly H. Vivas

**Senior Production Coordinator:** Amy B. Brooks

**Production Coordinators:** Gianna Caradonna, Maria Volpati

**Data Manager:** Jeffrey D. Schaefer

**Senior Format Editor:** Gregory J. Westley

**Index Editors:** Johanna M. Mazur, Robert N. Woerner

**Art Associate:** Joan K. Akerlind

**Senior Digital Imaging Coordinator:** Shawn W. Cahill

**Digital Imaging Coordinator:** Frank J. McElroy, III

**Electronic Publishing Designer:** Livio Udina

**Fulfillment Manager:** Stephanie DeNardi



Copyright © 2000 and published by Medical Economics Company, Inc. at Montvale, NJ 07645-1742. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. PHYSICIANS' DESK REFERENCE®, PDR®, PDR For Ophthalmology®, Pocket PDR®, and The PDR® Family Guide to Prescription Drugs® are registered trademarks used herein under license. PDR For Nonprescription Drugs and Dietary Supplements™, PDR Companion Guide™, PDR® for Herbal Medicines™, PDR® Medical Dictionary™, PDR® Nurse's Drug Handbook™, PDR® Nurse's Dictionary™, The PDR® Family Guide Encyclopedia of Medical Care™, The PDR® Family Guide to Natural Medicines and Healing Therapies™, The PDR® Family Guide to Common Ailments™, The PDR® Family Guide to Over-the-Counter Drugs™, and PDR® Electronic Library™ are trademarks used herein under license.

**Officers of Medical Economics Company:** President and Chief Executive Officer: Curtis B. Allen; Vice President, New Media: L. Suzanne BeDell; Vice President, Corporate Human Resources: Pamela M. Bilash; Vice President and Chief Information Officer: Steven M. Bressler; Chief Financial Officer: Christopher Caridi; Vice President and Controller: Barry Gray; Vice President, New Business Planning: Linda G. Hope; Vice President, Business Integration: David A. Pitler; Vice President, Finance: Donna Santaripa; Senior Vice President, Directory Services: Paul Walsh; Senior Vice President, Operations: John R. Ware; Senior Vice President, Internet Strategies: Raymond Zoeller



Printed on recycled paper

ISBN: 1-56363-330-2



**RabAvert—Cont.**

years and, if the titer is less than complete neutralization at a 1:5 serum dilution by RFFIT, should have a booster dose of vaccine. Alternatively, a booster can be administered in the absence of a titer determination.

Veterinarians and animal-control and wildlife officers working in areas of low rabies enzooticity (infrequent-exposure group) do not require routine pre-exposure booster doses of RabAvert after completion of a full primary pre-exposure immunization scheme (Table 1).

**B. Post-exposure Dosage**

**Immunization should begin as soon as possible after exposure.** A complete course of immunization consists of a total of 5 injections of 1 mL each: one injection on each of days 0, 3, 7, 14 and 28 in conjunction with the administration of HRIG on day 0. For children, see *Pediatric Use* section, above.

Begin with the administration of HRIG. Give 20 IU/kg body weight.

This formula is applicable to all age groups, including children. The recommended dosage of HRIG should not exceed 20 IU/kg body weight because it may otherwise interfere with active antibody production. Since vaccine-induced antibody appears within 1 week, HRIG is not indicated more than 7 days after initiating post-exposure immunization with RabAvert. If possible, up to one-half the dose of HRIG should be thoroughly infiltrated in the area around the wound and the rest should be administered IM, in a different site from the rabies vaccine, preferably in the gluteal area.

Because the antibody response following the recommended immunization regimen with RabAvert has been satisfactory, routine post-immunization serologic testing is not recommended. Serologic testing is indicated in unusual circumstances, as when the patient is known to be immunosuppressed. Contact state health department or CDC for recommendations.

**C. Post-exposure Therapy of Previously Immunized Persons**

When rabies exposure occurs in an immunized person who was vaccinated according to the recommended regimen with RabAvert or other tissue culture vaccines or who had previously demonstrated rabies antibody, that person should receive two IM doses (1.0 mL each) of RabAvert: one immediately and one 3 days later. HRIG should not be given in these cases. Persons should be considered to have been immunized previously if they received pre- or post-exposure prophylaxis with RabAvert or other tissue culture vaccines or have been documented to have had an adequate antibody response to duck embryo rabies vaccine. If the immune status of a previously vaccinated person is not known, full primary post-exposure antirabies treatment (HRIG plus 5 doses of vaccine) may be necessary. In such cases, if antibodies can be demonstrated in a serum sample collected before vaccine is given, treatment can be discontinued after at least two doses of vaccine.

**HOW SUPPLIED**

Package with:

- 1 vial of freeze-dried vaccine containing a single dose
- 1 disposable syringe
- 1 longer needle for reconstitution, 21 gauge × 1.5"
- 1 vial of sterile Water For Injection, USP (1 mL)
- 1 smaller needle for injection, 25 gauge × 1"
- N.D.C.# 53905-501-01 CAUTION: Federal law prohibits dispensing without a prescription

**Storage**

RabAvert should be stored protected from light at 2°C to 8°C (36°F to 46°F). After reconstitution the vaccine is to be used immediately. The vaccine may not be used after the expiration date given on package and container.

**REFERENCES**

1. Smith JS, Yager PA & Baer GM. A rapid reproducible test for determining rabies neutralisation antibody. *Bull WHO*. 1973; 48: 535-541.
2. Eighth Report of the WHO Expert Committee on Rabies. WHO Technical Report Series, no. 824; 1992.
3. Dreesen DW, et al. Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization. *Vaccine*. 1989; 7: 397-400.
4. Dreesen DW. Investigation of antibody response to purified chick embryo cell tissue culture vaccine (PCECV) or human diploid cell culture vaccine (HDCV) in health volunteers. Study synopsis 7USA401RA, September 1996-December 1996 (unpublished).
5. Nicholson KG, et al. Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine: serological and clinical responses in man. *Vaccine*. 1987; 5: 208-210.
6. Vodopija I, et al. An evaluation of second generation tissue culture rabies vaccine for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 post-exposure schedule. *Vaccine*. 1986; 4: 245-248.
7. Wasi C, et al. Purified chick embryo cell rabies vaccine (letter). *Lancet*. 1986; 1: 40.
8. Wasi C. Rabies prophylaxis with purified chick embryo (PCEC) rabies vaccine. Protocol 8T—201RA, 1983-1984 (unpublished).
9. Wasi C. Personal communication to Behringwerke AG, 1990.

10. Bijok U, et al. Clinical trials in healthy volunteers with the new purified chick embryo cell rabies vaccine for man. *J Commun Dis*. 1984; 16: 61-69.
11. Vodopija I. Post-exposure rabies prophylaxis with purified chick embryo cell (PCEC) rabies vaccine. Protocol 7YU-201RA, 1983-1985 (unpublished).
12. John J. Evaluation of purified chick embryo cell culture (PCEC) rabies vaccine, 1987 (unpublished).
13. Tanphaichitra D, Siristonpun Y. Study of the efficacy of a purified chick embryo cell vaccine in patients bitten by rabid animals. *Intern Med*. 1987; 3: 158-160.
14. Thongcharoen P, et al. Effectiveness of new economical schedule of rabies postexposure prophylaxis using purified chick embryo cell tissue culture rabies vaccine. Protocol 7T—301IP, 1993 (unpublished).
15. Ljubicic M, et al. Efficacy of PCEC vaccines in post-exposure rabies prophylaxis. In: Vodopija, Nicholson, Smerdel & Bijok (eds.): Improvements in rabies post-exposure treatment (Proceedings of a meeting in Dubrovnik, Yugoslavia). Zagreb Institute of Public Health 1985.
16. Madhusudana SN, Tripathi KK. Post exposure studies with human diploid cell rabies vaccine and purified chick embryo cell vaccine: Comparative Serological Responses in Man. *Int. Med Microbiol*. 1989; 271: 345-350.
17. Sehgal S, et al. Ten year longitudinal study of efficacy and safety of purified chick embryo cell vaccine for pre- and post-exposure prophylaxis of rabies in Indian population. *J Commun Dis*. 1995; 27: 36-43.
18. Sehgal S, et al. Clinical evaluation of purified chick embryo cell antirabies vaccine for post-exposure treatment. *J Commun Dis*. 1988; 20: 293-300.
19. Suntharasamai P, et al.: Purified chick embryo cell rabies vaccine: economical multisite intradermal regimen for post-exposure prophylaxis. *Epidemiol Infect*. 1987; 99; (3): 755-765.
20. Meesomboon V, et al. Antibody response to PCEC-rabies vaccine. *J. Commun Dis*. 1987; 13: 130-136.
21. Sehgal S. Report of the trials of PCEC (Purified Chick Embryo Cell) rabies vaccine in India. In: Vodopija, Nicholson, Smerdel & Bijok (eds.): Improvements in rabies post-exposure treatment (Proceedings of a meeting in Dubrovnik, Yugoslavia). Zagreb Institute of Public Health 1985 pp. 71-75.
22. Lesic L, Petrovic M. Study Report: Findings of Clinical Trials on Rabipur PCEC, Rabies Vaccine, National Reference Laboratory for Rabies, Novi Sad, Yugoslavia, 1988 (unpublished).
23. Centers for Disease Control. Rabies Prevention - United States, 1991. Recommendations of the Immunization Practices Advisory Committee (ACIP). *MMWR*, 1991; 40 (RR-3): 1-19.
24. Dreesen D, et al.: A comparative study of cell culture rabies vaccine: Immunogenicity and safety. Protocol 8USA301RA, 1985-1986 (unpublished).
25. Centers for Disease Control. Systemic allergic reactions following immunization with HDC rabies vaccine. *MMWR*. 1984; 33: 185-187.
26. Centers for Disease Control. Rabies Prevention - United States. *MMWR*. 1984; 33: 393-402.
27. Dreesen DW, et al. Immune complex-like disease in 23 persons following a booster dose of rabies HDC vaccine. *Vaccine*. 1986; 4: 45-49.
28. Anderson MC, et al. The role of specific IgE and beta-propiolactone in reactions resulting from booster dose of human diploid rabies cell vaccine. *J Allergy Clin Immunol*. 1987; 80: 861-868.
29. Swanson MC, et al. IgE and IgG antibodies to beta-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine. *J Infect Dis*. 1987; 155: 909-913.
30. Marwick C. Changes recommended in use of human diploid cell rabies vaccine (news). *JAMA*. 1985; 245: 14-15.
31. Lumbiganon P, Wasi C. Survival after rabies immunisation in newborn infant of affected mother. *Lancet*. 1990; 336: 319-322.
32. Lumbiganon P, et al. Pre-exposure vaccination with purified chick embryo cell rabies vaccines in children. *Asian Pacific J Allergy Immunol*. 1989; 7: 99-101.
33. Gonzales de Ciso. Comparative evaluation of PCEC and Fluenzalida vaccines. Protocol 8Mex201RA, 1983-1984 (unpublished).

**Manufactured by:**  
Chiron Behring GmbH & Co,  
D-35006 Marburg, Germany

**Distributed by:**  
Chiron Corporation  
Emeryville, CA 94608, USA

Rev. 10/97

Shown in Product Identification Guide, page 310

For EMERGENCY telephone numbers,  
consult the **Manufacturers' Index**.

**CibaGeneva Pharmaceuticals**

**Ciba-Geigy Corporation**

**Geneva Pharmaceuticals, Inc.**

**PLEASE NOTE:**

Due to the merger of CibaGeneva Pharmaceuticals and Sandoz Pharmaceuticals Corporation, please refer to **Novartis Pharmaceuticals Corporation** for branded product information and **Geneva Pharmaceuticals, Inc.** for branded generic product information.

**Colgate Oral Pharmaceuticals, Inc.**

**a subsidiary of Colgate-Palmolive Company**  
**ONE COLGATE WAY**  
**CANTON, MA 02021 U.S.A.**

**Direct Inquiries to:**  
Professional Services Department  
(800) 226-5428

**For Medical Information Contact:**

**In Emergencies:**  
Pittsburgh Poison Control  
(412) 692-5596

**LURIDE® DROPS**  
brand of sodium fluoride  
oral solution

1.69 fl oz (50 mL) bottles, calibrated dropper

**LURIDE® LOZI-TABS®**  
brand of sodium fluoride

120 tablet bottles 0.25 mg F vanilla  
120 tablet bottles 0.5 mg F grape  
120 tablet bottles 1 mg F cherry

**PERIOGARD®**  
(chlorhexidine gluconate  
oral rinse, 0.12%)

16 fl oz bottles

**PREVIDENT 5000 PLUS®**  
brand of 1.1% Sodium Fluoride  
prescription dental cream

1.8 oz. (51g) net wt. tubes Spearmint or Fruitastic™  
Twin Pack (two 1.8 oz (51g) net wt. tubes) Spearmint

**CollaGenex Pharmaceuticals, Inc.**


**41 UNIVERSITY DRIVE**  
**NEWTOWN, PA 18940**

**Direct inquiries to:**  
888-339-5678

**PERIOSTAT®**  
[perio-stat]  
(doxycycline hyclate capsules)

**DESCRIPTION**

Periostat® is available as a 20 mg capsule formulation of doxycycline hyclate for oral administration. Doxycycline is synthetically derived from oxytetracycline. The structural formula of doxycycline hyclate is:



with an empirical formula of (C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>8</sub>·HCl)·C<sub>2</sub>H<sub>5</sub>O·H<sub>2</sub>O and a molecular weight of 1025.89. The chemical designation for doxycycline is 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-

pentahydroxy-6-methyl-1,11-dioxo-2-naphthacene-carboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate.

Doxycycline hyclate is a light-yellow crystalline powder which is soluble in water.

Inert ingredients in the formulation are: hard gelatin capsules; magnesium stearate; and microcrystalline cellulose. Each capsule contains doxycycline hyclate equivalent to 20 mg of doxycycline.

#### CLINICAL PHARMACOLOGY

After oral administration, doxycycline hyclate is rapidly and nearly completely absorbed from the gastrointestinal tract. Doxycycline is eliminated with a half-life of approximately 18 hours by renal and fecal excretion of unchanged drug.

**Mechanism of Action:** Doxycycline has been shown to inhibit collagenase activity *in vitro*.<sup>1</sup> Additional studies have shown that doxycycline reduces the elevated collagenase activity in the gingival crevicular fluid of patients with adult periodontitis.<sup>2-3</sup> The clinical significance of these findings is not known.

**Microbiology:** Doxycycline is a member of the tetracycline class of antibiotics. The dosage of doxycycline achieved with this product during administration is well below the concentration required to inhibit microorganisms commonly associated with adult periodontitis. Clinical studies with this product demonstrated no effect on total anaerobic and facultative bacteria in plaque samples from patients administered this dose regimen for 9 to 18 months. This product should not be used for reducing the numbers of or eliminating those microorganisms associated with periodontitis.

#### Pharmacokinetics

The pharmacokinetics of doxycycline following oral administration of Periostat® were investigated in 3 volunteer studies involving 87 adults. Additionally, doxycycline pharmacokinetics have been characterized in numerous scientific publications.<sup>4</sup> Pharmacokinetic parameters for Periostat® following single oral doses and at steady-state in healthy subjects are presented as follows:

[See first table above]

**Absorption:** Doxycycline is virtually completely absorbed after oral administration. Following 20 mg doxycycline, twice a day, in healthy volunteers, the mean peak concentration in plasma was 790 ng/mL and the average steady-state concentration was 482 ng/mL. The effect of food on the absorption of doxycycline from Periostat® has not been studied.

**Distribution:** Doxycycline is greater than 90% bound to plasma proteins. Its apparent volume of distribution is variously reported as between 52.6 and 134 L.<sup>4,6</sup>

**Metabolism:** Major metabolites of doxycycline have not been identified. However, enzyme inducers such as barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.

**Excretion:** Doxycycline is excreted in the urine and feces as unchanged drug. It is variously reported that between 29% and 55.4% of an administered dose can be accounted for in the urine by 72 hours.<sup>5,6</sup> Half-life averaged 18 hours in subjects receiving a single 20 mg doxycycline dose.

#### Special Populations

**Geriatric:** Doxycycline pharmacokinetics have not been evaluated in geriatric patients.

**Pediatric:** Doxycycline pharmacokinetics have not been evaluated in pediatric patients. (See WARNINGS.)

**Gender:** A study was conducted in 42 subjects where doxycycline pharmacokinetics were compared in men and women. It was observed that  $C_{max}$  was approximately 1.7-fold higher in women than in men. There were no apparent differences in other pharmacokinetic parameters.

**Race:** Differences in doxycycline pharmacokinetics among racial groups have not been evaluated.

**Renal Insufficiency:** Studies have shown no significant difference in serum half-life of doxycycline in patients with normal and severely impaired renal function. Hemodialysis does not alter the half-life of doxycycline.

**Hepatic Insufficiency:** Doxycycline pharmacokinetics have not been evaluated in patients with hepatic insufficiency.

**Drug Interactions:** See "Precautions"

#### Clinical Study

In a randomized, multi-centered, double-blind, 9-month Phase 3 study involving 190 adult patients with periodontal disease [at least two probing sites per quadrant of between 5 and 9 mm pocket depth (PD) and attachment level (AL)], the effects of oral administration of 20 mg twice a day of doxycycline hyclate plus scaling and root planing (SRP) were compared to placebo control plus SRP. Both treatment groups were administered a course of scaling and root planing in 2 quadrants at Baseline. Measurements of AL, PD and bleeding-on-probing (BOP) were obtained at Baseline, 3, 6, and 9 months from each site about each tooth in the two quadrants that received SRP using the UNC-15 manual probe. Each tooth site was categorized into one of three strata based on Baseline PD: 0-3 mm (no disease), 4-6 mm (mild/moderate disease),  $\geq 7$  mm (severe disease). For each stratum and treatment group, the following were calculated at month 3, 6, and 9: mean change in AL from baseline, mean change in PD from baseline, mean percentage of tooth sites per patient exhibiting attachment loss of  $\geq 2$  mm from baseline, and percentage of tooth sites with bleeding on probing. The results are summarized in the following table. [See second table above]

#### INDICATIONS AND USAGE

Periostat® is indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis.

#### Pharmacokinetic Parameters for Periostat®

	n	C <sub>max</sub> (ng/mL)	T <sub>max</sub> (hr)	Cl/F (L/hr)	t <sub>1/2</sub> (hr)
Single dose 20 mg	42	400 ± 142	1.5 (0.5-4.0)	3.80 ± 0.85	18.4 ± 5.38
Steady-State 20 mg BID	30	790 ± 285	2 (0.98-12.0)	3.76 ± 1.06	Not Determined

#### Clinical Results at Nine Months as an Adjunct to SRP

Parameter	0-3 mm 90	Baseline Pocket Depth 4-6 mm 90	$\geq 7$ mm 79
<b>Number of Patients</b>			
Mean Gain in ALV			
Periostat® 20 mg BID	0.25 mm	1.03 mm*	1.55 mm*
Placebo	0.20 mm	0.86 mm	1.17 mm
Mean Decrease in PD			
Periostat® 20 mg BID	0.16 mm**	0.95 mm**	1.68 mm**
Placebo	0.05 mm	0.69 mm	1.20 mm
% of Sites with loss of ALV $\geq 2$ mm			
Periostat® 20 mg BID	1.9%	1.3%	0.3%*
Placebo	2.2%	2.4%	3.6%
% of Sites with BOP			
Periostat® 20 mg BID	39%**	64%*	75%
Placebo	46%	70%	80%

\*p<0.050 vs. the placebo control group.

\*\*p<0.010 vs. the placebo control group.

#### CONTRAINDICATIONS

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

#### WARNINGS

**THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN).** This adverse reaction is more common during long-term use of the drugs but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. **TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP AND IN PREGNANT OR NURSING MOTHERS UNLESS THE POTENTIAL BENEFITS MAY BE ACCEPTABLE DESPITE THE POTENTIAL RISKS.**

All tetracyclines form a stable calcium complex in any bone forming tissue. A decrease in fibula growth rate has been observed in premature infants given oral tetracyclines in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued.

Doxycycline can cause fetal harm when administered to a pregnant woman. Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. If any tetracyclines are used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

The catabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.

Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.

#### PRECAUTIONS

While no overgrowth by opportunistic microorganisms such as yeast were noted during clinical studies, as with other antimicrobials, Periostat® therapy may result in overgrowth of nonsusceptible microorganisms including fungi. The use of tetracyclines may increase the incidence of vaginal candidiasis.

Periostat® should be used with caution in patients with a history or predisposition to oral candidiasis. The safety and effectiveness of Periostat® has not been established for the treatment of periodontitis in patients with coexistent oral candidiasis.

If superinfection is suspected, appropriate measures should be taken.

**Laboratory Tests:** In long term therapy, periodic laboratory evaluations of organ systems, including hematopoietic, renal, and hepatic studies should be performed.

**Drug Interactions:** Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

Since bacteriostatic antibiotics, such as the tetracycline class of antibiotics, may interfere with the bactericidal ac-

tion of members of the b-lactam (e.g. penicillin) class of antibiotics, it is not advisable to administer these antibiotics concomitantly.

Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and by iron-containing preparations. Absorption is also impaired by bismuth subsalicylate.

Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.

The concurrent use of tetracycline and Penthrane (methoxy-fluorane) has been reported to result in fatal renal toxicity. Concurrent use of tetracycline may render oral contraceptives less effective.

**Drug/Laboratory Test Interactions:** False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Doxycycline hyclate has not been evaluated for carcinogenic potential in long-term animal studies. Evidence of oncogenic activity was obtained in studies with related compounds, i.e., oxytetracycline (adrenal and pituitary tumors), and minocycline (thyroid tumors).

Doxycycline hyclate demonstrated no potential to cause genetic toxicity in an *in vitro* point mutation study with mammalian cells (CHO/HGPRT forward mutation assay) or in an *in vivo* micronucleus assay conducted in CD-1 mice. However, data from an *in vitro* assay with CHO cells for potential to cause chromosomal aberrations suggest that doxycycline hyclate is a weak clastogen.

Oral administration of doxycycline hyclate to male and female Sprague-Dawley rats adversely affected fertility and reproductive performance, as evidenced by increased time for mating to occur, reduced sperm motility, velocity, and concentration, abnormal sperm morphology, and increased pre- and post-implantation losses. Doxycycline hyclate induced reproductive toxicity at all dosages that were examined in this study, as even the lowest dosage tested (50 mg/kg/day) induced a statistically significant reduction in sperm velocity. Note that 50 mg/kg/day is approximately 10 times the amount of doxycycline hyclate contained in the recommended daily dose of Periostat® for a 60 kg human when compared on the basis of body surface area estimates (mg/m<sup>2</sup>). Although doxycycline impairs the fertility of rats when administered at sufficient dosage, the effect of Periostat® on human fertility is unknown.

**Pregnancy: Teratogenic Effects:** Pregnancy Category D. (See WARNINGS.) Results from animal studies indicate that doxycycline crosses the placenta and is found in fetal tissues.

**Nonteratogenic effects:** (See WARNINGS.)

**Labor and Delivery:** The effect of tetracyclines on labor and delivery is unknown.

**Nursing Mothers:** Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from doxycycline, the use of Periostat® in nursing mothers is contraindicated. (See WARNINGS.)

**Pediatric Use:** The use of Periostat® in infancy and childhood is contraindicated. (See WARNINGS.)

#### ADVERSE REACTIONS

**Adverse Reactions in Clinical Trials of Periostat®:** In clinical trials of adult patients with periodontal disease 213 patients received Periostat® 20 mg BID over a 9-12 month period. The most frequent adverse reactions occurring in studies involving treatment with Periostat® or placebo are listed below:

Continued on next page

Consult 2000 PDR® supplements and future editions for revisions

**Periostat—Cont.**

Incidence (%) of Adverse Reactions in Periostat Clinical Trials		
Adverse Reaction	Periostat 20 mg BID (n=213)	Placebo (n=215)
Headache	55 (26%)	56 (26%)
Common Cold	47 (22%)	46 (21%)
Flu Symptoms	24 (11%)	40 (19%)
Tooth Ache	14 (7%)	28 (13%)
Periodontal Abscess	8 (4%)	21 (10%)
Tooth Disorder	13 (6%)	19 (9%)
Nausea	17 (8%)	12 (6%)
Sinusitis	7 (3%)	18 (8%)
Injury	11 (5%)	18 (8%)
Dyspepsia	13 (6%)	5 (2%)
Sore Throat	11 (5%)	13 (6%)
Joint Pain	12 (6%)	8 (4%)
Diarrhea	12 (6%)	8 (4%)
Sinus Congestion	11 (5%)	11 (5%)
Coughing	9 (4%)	11 (5%)
Sinus Headache	8 (4%)	8 (4%)
Rash	8 (4%)	6 (3%)
Back Pain	7 (3%)	8 (4%)
Back Ache	4 (2%)	9 (4%)
Menstrual Cramp	9 (4%)	5 (2%)
Acid Indigestion	8 (4%)	7 (3%)
Pain	8 (4%)	5 (2%)
Infection	4 (2%)	6 (3%)
Gum Pain	1 (%)	6 (3%)
Bronchitis	7 (3%)	5 (2%)
Muscle Pain	2 (1%)	6 (3%)

Note: Percentages are based on total number of study participants in each treatment group.

**Adverse Reactions for Tetracyclines:** The following adverse reactions have been observed in patients receiving tetracyclines:

Gastrointestinal: anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with vaginal candidiasis) in the anogenital region. Hepatotoxicity has been reported rarely. Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving the capsule forms of the drugs in the tetracycline class. Most of these patients took medications immediately before going to bed. (SEE DOSAGE AND ADMINISTRATION.)

Skin: maculopapular and erythematous rashes. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above. (See WARNINGS.)

Renal toxicity: Rise in BUN has been reported and is apparently dose related. (See WARNINGS.)

Hypersensitivity reactions: urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus. Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported.

**OVERDOSAGE**

In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdose.

**DOSAGE AND ADMINISTRATION**

THE DOSAGE OF PERIOSTAT® DIFFERS FROM THAT OF DOXYCYCLINE USED TO TREAT INFECTIONS. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS INCLUDING THE DEVELOPMENT OF RESISTANT MICROORGANISMS.

Periostat® 20 mg twice daily as an adjunct following scaling and root planing may be administered for up to 9 months. Safety beyond 12 months and efficacy beyond 9 months have not been established.

Periostat® should be administered at least one hour prior to morning and evening meals.

Administration of adequate amounts of fluid along with the capsules is recommended to wash down the drug and reduce the risk of esophageal irritation and ulceration. (SEE ADVERSE REACTIONS.)

**HOW SUPPLIED**

Periostat® (white capsule imprinted with "Periostat™") containing doxycycline hyclate equivalent to 20 mg doxycycline. Bottle of 100 (NDC 27280-007-01).

**Storage:** All products are to be stored at controlled room temperatures of 59°F–86°F (15°C–30°C) and dispensed in tight, light-resistant containers (USP).

**Rx Only**

PERIOSTAT® is a trademark of CollaGenex Pharmaceuticals, Inc., Newtown, PA 18940.

Manufactured by

Applied Analytical Inc.

Wilmington, NC 28403

Marketed by

CollaGenex Pharmaceuticals, Inc.

Newtown, PA 18940

U.S. Patents 4,666,897

and RE 34,656

**REFERENCES**

- Golub L.M., Sorsa T., Lee H.M., Ciancio S., Sorbi D., Ramamurthy N.S., Gruber B., Salo T., Kontinen Y.T.: Doxycycline Inhibits Neutrophil (PMN)-type Matrix Metalloproteinases in Human Adult Periodontitis Gingiva. *J. Clin. Periodontol* 1995; 22: 100–109.
- Golub L.M., Ciancio S., Ramamurthy N.S., Leung M., McNamara T.F.: Low-dose Doxycycline Therapy: Effect on Gingival and Crevicular Fluid Collagenase Activity in Humans. *J. Periodont Res* 1990; 25: 321–330.
- Golub L.M., Lee H.M., Greenwald R.A., Ryan M.E., Salo T., Giannobile W.V.: A Matrix Metalloproteinase Inhibitor Reduces Bone-type Collagen Degradation Fragments and Specific Collagenases in Gingival Crevicular Fluid During Adult Periodontitis. *Inflammation Research* 1997; 46: 310–319.
- Saivain S., Houin G.: Clinical Pharmacokinetics of Doxycycline and Minocycline. *Clin. Pharmacokinetics* 1988; 15: 355–366.
- Schach von Wittenau M., Twomey T.: The Disposition of Doxycycline by Man and Dog. *Chemotherapy* 1971; 16: 217–228.
- Campistrion G., Coulais Y., Caillard C., Mosser J., Pontagnier H., Houin G.: Pharmacokinetics and Bioavailability of Doxycycline in Humans. *Arzneimittel Forschung* 1986; 36: 1705–1707.

**Cooke Pharma**  
**1404 OLD COUNTY ROAD**  
**BELMONT, CA 94002**

**Direct Inquiries to:**  
 Customer Service Dept.  
 (888) 808-6838

**HEARTBAR™**  
**L-arginine-enriched**  
**Medical Food**

**OTC****DESCRIPTION**

The HeartBar™ is a formulation of nutrients and vitamins for the dietary management of cardiovascular disease. These ingredients are placed in a convenient and pleasant-tasting nutrition bar. The major active ingredient in the HeartBar is L-arginine, which is an amino acid required for the production of nitric oxide (NO). Each 50g bar contains L-arginine (3 g) and other amino acids, folate (200 µg) and other B-complex vitamins, antioxidant vitamins E (200 IU) and C (250 mg), niacin (25 mg) and phytoestrogens. These nutrients are combined in a fruit, fiber, and soy protein-based nutrition bar. One HeartBar contains 13 g of protein, 27 g of carbohydrate (20 g of sugars, 3 g of fiber), 3 g of fat (1 g saturated fat, 0 mg of cholesterol), and 190 calories. HeartBar does not require a prescription but is to be used under the supervision of a health care professional.

**COMPOSITION (original flavor)**

High fructose corn syrup, soy protein isolate, fructose, toasted soy pieces, raisins, vanilla cookie pieces (including wheat flour), L-arginine HCl, natural and artificial flavors, oat fiber, DL-alpha-tocopherol acetate, sodium ascorbate, dipotassium phosphate, niacinamide, pyridoxine hydrochloride, folic acid, cyanocobalamin.

**CLINICAL BACKGROUND**

The major active ingredient of the HeartBar, L-arginine, is a semi-essential amino acid, and is the precursor for endothelium-derived nitric oxide (NO). NO is a potent vasodilator, and a major regulator of vasomotion and blood pressure. In addition, NO inhibits platelet aggregation, vascular smooth muscle proliferation and adherence of leukocytes to the vessel wall, key processes in atherosclerosis and restenosis.

Endothelium-derived NO activity is reduced in patients with cardiovascular disease; this abnormality contributes to

insufficient blood flow, elevated blood pressure, as well as progression of disease. L-arginine has been shown to enhance the synthesis of NO. In humans, L-arginine improves vasodilation, enhances coronary and peripheral blood flow, and inhibits platelet aggregation.

The usual dietary intake of L-arginine is about 5 g/day, which in some cardiovascular conditions, may not be sufficient intake to maintain healthy NO levels. Two HeartBars/day provides an additional 6 g of L-arginine. The other active ingredients of the HeartBar contribute to the production, or help prevent the breakdown of NO further augmenting the activity of NO.

The HeartBar has been tested clinically in several patient populations and shown to be effective in improving blood flow. In two separate studies of individuals with total cholesterol over 230 mg/dl (n=41 & n=39), two HeartBars/day restored flow-mediated vasodilation to normal within one and two weeks respectively (compared to no change with placebo). In patients with peripheral arterial disease secondary to atherosclerosis (n=39), 2 HeartBars/day improved pain-free walking distance by 66% (compared to placebo of 18%). In addition to this improvement in physical function, these patients experienced an improvement in quality of life scores as measured by the SF-36 Medical Outcomes Survey.

**PHARMACOKINETICS**

Following the administration of 1 HeartBar, plasma arginine levels rise from 68±27 µM/L to a peak of 119±48 µM/L within one hour of ingestion. Arginine levels are maintained above those of individuals on an arginine-free diet for at least 8 hours after ingestion. A similar pattern of arginine levels is observed following the ingestion of a single HeartBar after a week of b.i.d. use. After 2 weeks, trough L-arginine levels are 42% higher than levels before HeartBar use. These arginine levels compare favorably with L-arginine administration by capsular form.

**PRECAUTIONS****Diabetics**

The HeartBar contains 190 calories, 27g of carbohydrate (20g of sugars) and 3 g of fat. Diabetics should monitor their blood glucose carefully while initiating regular use of the HeartBar. The effect of L-arginine on retinopathy is not known, therefore, those with diabetic retinopathy should not use Heartbar.

**Renal Failure Patients**

The HeartBar contains 13 g of protein. This amount of protein should be considered when determining total daily protein load.

**Allergies**

The base of the bar is of soy protein, which is generally considered hypoallergenic. The original flavor also contains a small amount of wheat flour. Therefore, individuals with allergies to wheat products should be cautious.

**Sepsis**

The hypotension associated with sepsis is, in-part, mediated by excessive NO production. Such patients should not be given HeartBar.

**ADVERSE REACTIONS**

No serious adverse reactions have been demonstrated or reported in clinical trials or in the HeartBar Safety-In-Use study.

Minor adverse reactions are infrequent, generally related to gastrointestinal disturbances and appear unrelated to the L-arginine in the bar (Adverse events were just as common in the group given placebo bar). In a two-week study of the HeartBar, 4 of 41 individuals reported increased flatulence that resolved after several days of bar use. One of 41 individuals complained of increased frequency of bowel movements and soft stools. In a 10-week study of the HeartBar, 2 of 41 individuals reported dry mouth. A change in bowel habits was reported by 1 individual in each of the placebo and HeartBar groups.

The HeartBar is not indicated for individuals with co-existing conditions of diabetic retinopathy, neoplastic disease or inflammatory arthritis because the effect of L-arginine on the progression of these disorders is unknown.

**ADMINISTRATION****Symptomatic or High-Risk Population**

One HeartBar twice daily

**At-risk Population**

One HeartBar daily

**HOW SUPPLIED**

Individually wrapped bars, cartons of 16 and cases of 64.

**Original Flavor**

Individual Bars NDC 63535-10102

By Carton NDC 63535-10103

By Case NDC 63535-10104

**Cranberry Flavor**

Individual Bars NDC 63535-10202

By Carton NDC 63535-10203

By Case NDC 63535-10104

**REFERENCES**

- Cooke, J.P., and Dzau, V.J. (1997). *Annu Rev Med* 48, 489–509.
- Maxwell, A.J., and Anderson, B.A. (1999). *J Am Coll Cardiol* 33, 277A.
- Maxwell, A.J., and Anderson, B.A. (1999). *J Am Coll Cardiol* 33, 282A.
- Maxwell, A.J., and Cooke, J.P. (1998). *Curr Opin Nephrol Hypertens* 7, 63–70.